Cancer News and Research

Latest Cancer News and Research

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Bon-Ton Stores to conduct “Shop for a Cure” event to support breast cancer research

The Bon-Ton Stores, Inc. announced today the official kick-off to National Breast Cancer Awareness Month with special promotions to support breast cancer research. On Wednesday, October 7, Bon-Ton will hold a “Shop for a Cure” one-day shopping event. The Company will donate 1% of all purchases made on its proprietary credit card on October 7 to fund breast cancer research.

5 Oct 2009

PrimeraDx receives its fourth patent

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled “Methods and systems for dynamic gene expression profiling”, with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations.

5 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.

5 Oct 2009

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.

5 Oct 2009

Oral Cancer Foundation initiates program to donate VELscope screening systems

The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.

5 Oct 2009

Genzyme named to the 2009 Dow Jones Sustainability World Index

Genzyme Corporation announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index.

5 Oct 2009

Willow Breast Cancer Support Canada calls for national Metastatic Breast Cancer Awareness Day

Thousands of Canadian women with metastatic breast cancer and their loved ones are marking the first Canadian Metastatic Breast Cancer Awareness Day on October 13, urging Canadians to acknowledge them and delivering the message that "hope changes."

5 Oct 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets.

5 Oct 2009

Prostate cancer and its influence on men's daily lives

Men who have prostate cancer often feel quite healthy, but the diagnosis still gives them a whole new outlook on life. Once they have learned to live with their cancer, they choose to focus on valuable relationships and appreciate the little things in life, shows a dissertation thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

5 Oct 2009

Cord Blood America reduces its secured debt by $160,000

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has retired a note, principal amount $160,000, in its continuing effort to reduce debt.

5 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

Tools to educate employees about disability threats

The Council for Disability Awareness (CDA) is alerting all employers that disabling illnesses have become one of the fastest growing threats to employees' income. In fact, they now account for 55 percent of workplace absences.

5 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Bon-Ton Stores to conduct “Shop for a Cure” event to support breast cancer research

PrimeraDx receives its fourth patent

Preclinical study results of AVL-181 protease inhibitor presented

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Oral Cancer Foundation initiates program to donate VELscope screening systems

Genzyme named to the 2009 Dow Jones Sustainability World Index

Willow Breast Cancer Support Canada calls for national Metastatic Breast Cancer Awareness Day

Fifth SEEM anniversary meeting to be held in Belgrade

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Prostate cancer and its influence on men's daily lives

Cord Blood America reduces its secured debt by $160,000

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Tools to educate employees about disability threats

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in